MSLN and ovarian carcinoma: Currently, there is an ongoing phase I clinical trial evaluating the oncovirus VCN-1 administered in combination with human CAR-T cells targeting mesothelin in patients with unresectable or metastatic pancreatic or persistent or recurrent ovarian cancer (NCT05057715).